These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8987966)

  • 1. Extracellular matrix and cardiovascular diseases.
    Ju H; Dixon IM
    Can J Cardiol; 1996 Dec; 12(12):1259-67. PubMed ID: 8987966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of static and cyclic loading in regulating extracellular matrix synthesis by cardiovascular cells.
    Gupta V; Grande-Allen KJ
    Cardiovasc Res; 2006 Dec; 72(3):375-83. PubMed ID: 17010955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M
    Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist.
    Haddad GE; Blackwell K; Bikhazi A
    Can J Physiol Pharmacol; 2003 Feb; 81(2):142-9. PubMed ID: 12710528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of cardiac fibrosis by transforming growth factor-beta(1).
    Lijnen PJ; Petrov VV; Fagard RH
    Mol Genet Metab; 2000; 71(1-2):418-35. PubMed ID: 11001836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart.
    Collins AR; Schnee J; Wang W; Kim S; Fishbein MC; Bruemmer D; Law RE; Nicholas S; Ross RS; Hsueh WA
    J Am Coll Cardiol; 2004 May; 43(9):1698-705. PubMed ID: 15120833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Renin-angiotensin system and its role in cardiovascular physiopathology and therapy].
    Castro-Chaves P; Leite-Moreira AF
    Rev Port Cardiol; 2004 May; 23 Suppl 2():II61-77. PubMed ID: 15222251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure.
    Klotz S; Danser AH; Foronjy RF; Oz MC; Wang J; Mancini D; D'Armiento J; Burkhoff D
    J Am Coll Cardiol; 2007 Mar; 49(11):1166-74. PubMed ID: 17367660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and potential role of the extracellular matrix in hepatic ontogenesis: a review.
    Amenta PS; Harrison D
    Microsc Res Tech; 1997 Nov; 39(4):372-86. PubMed ID: 9407547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The bioactivity of angiotensin II and the effects of related Chinese Herbs].
    Shen YH; Chen CX
    Zhongguo Zhong Yao Za Zhi; 2003 May; 28(5):394-7, 431. PubMed ID: 15139119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on beta-adrenoceptor signaling in heart failure produced by myocardial Infarction in rabbits: reversal of altered expression of beta-adrenoceptor kinase and G i alpha.
    Makino T; Hattori Y; Matsuda N; Onozuka H; Sakuma I; Kitabatake A
    J Pharmacol Exp Ther; 2003 Jan; 304(1):370-9. PubMed ID: 12490614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of fibrin matrix composition to enhance endothelial cell growth and extracellular matrix deposition for in vitro tissue engineering.
    Pankajakshan D; Krishnan LK
    Artif Organs; 2009 Jan; 33(1):16-25. PubMed ID: 19178437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats.
    Deten A; Hölzl A; Leicht M; Barth W; Zimmer HG
    J Mol Cell Cardiol; 2001 Jun; 33(6):1191-207. PubMed ID: 11444923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
    Sandmann S; Unger T
    Drugs; 2002; 62 Spec No 1():43-52. PubMed ID: 12036388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
    Pasquale PD; Stefano GD; Paterna S
    Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.